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Abstract
Phosphoinositide 3-kinase (PI3K) pathway, in addition to its pro-proliferative and antiapoptotic effects on tumor cells,
contributes to DNA damage repair (DDR). We hypothesized that GDC-0980, a dual PI3K-mammalian target of
rapamycin (mTOR) inhibitor, would induce an efficient antitumor effect in BRCA-competent triple negative breast
cancer (TNBC) model when combined with ABT888 and carboplatin. Mechanism-based in vitro studies demonstrated
that GDC-0980 treatment alone or in combination led to DNA damage (increased pγH2AXS139; Western blot, immuno-
fluorescence), gain in poly ADP-ribose (PAR), and a subsequent sensitization of BRCA-competent TNBC cells to
ABT888 plus carboplatin with a time-dependent 1) decrease in proliferation signals (pAKTT308/S473, pP70S6KT421/S424,
pS6RPS235/236), PAR/poly(ADP-ribose) polymerase (PARP) ratios, PAR/pγH2AX ratios, live/dead cell ratios, cell cycle
progression, and three-dimensional clonogenic growths and 2) increase in apoptosis markers (cleaved caspases 3
and 9, a pro-apoptotic BH3-only of Bcl-2 family (BIM), cleaved PARP, annexin V). The combination was effective
in vitro in BRCA–wild-type PIK3CA-H1047R–mutated BT20 and PTEN-null HCC70 cells. The combination blocked
the growth of established xenograft tumors by 80% to 90% with a concomitant decrease in tumor Ki67, CD31,
phosphorylated vascular endothelial growth factor receptor, pS6RPS235/236, and p4EBP1T37/46 as well as an increase
in cleaved caspase 3 immunohistochemistry (IHC) levels. Interestingly, a combination with GDC-0941, a pan-PI3K
inhibitor, failed to block the tumor growth in MDA-MB231. Results demonstrate that the dual inhibition of PI3K and
mTOR regulates DDR. In a BRCA-competent model, GDC-0980 enhanced the antitumor activity of ABT888 plus
carboplatin by inhibiting both tumor cell proliferation and tumor-induced angiogenesis along with an increase in
the tumor cell apoptosis. This is the first mechanism-based study to demonstrate the integral role of the PI3K-AKT-
mTOR pathway in DDR-mediated antitumor action of PARP inhibitor in TNBC.
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Introduction
Poly(ADP-ribose) polymerase (PARP) has been the most promising
target in the triple negative (TN) subset of breast cancer (BC), the
most aggressive BC subset with limited options for a targeted therapy
[1–6]. As a nick-sensor, PARP binds to and initiates the repair of DNA
single-strand breaks (SSBs). A failure to repair these events leads to
persistent SSBs, which otherwise gets converted into potentially clasto-
genic or lethal double-strand breaks (DSBs) at the “replication fork.”
DSBs are corrected by either homologous recombination (HR) or non-
homologous end joining (NHEJ). However, DNA repair by HR, but
not by NHEJ, is reported to be elevated in BC cells [7]. Thus, PARP
inhibitors (PARPi) have potential chemosensitizing, radiosensitizing,
and antineoplastic activities [8–10]. PARPi have so far shown the most
promising effects in the BRCA1/2-deficient patient population, owing
to their ability to induce “synthetic lethality” [9,11,12], mediated
through the accumulation of structural DNA lesions, the correction
of which requires a coordinated action of a number of DNA damage
repair (DDR) enzymes. However, BRCA1/2 mutations account for
only 2% to 3%of all BCs, and thus, a significant percentage of the popu-
lation of TN and/or basal-type BC patients remains BRCA competent
[5] for whom PARPi as a single agent offers a very limited therapeutic
opportunity [3,13]. To date, studies to extend the use of PARPi outside
the “BRCA box” were inadequate and inconclusive [14].
The phosphoinositide 3-kinase (PI3K) enzyme contributes to repair
of DSB in addition to its role in pro-proliferative and antiapoptotic
functions in tumor cells [15]. Recently, the PI3K enzyme has been
demonstrated to play a critical role in RAD51 recruitment [16]. The
PI3K signaling pathway has been reported to maintain HR steady state
and stabilize and preserve DSB repair by interacting with the HR
complex [15]. Suppression of PI3K function has been shown to impair
HR [17]. Mammalian target of rapamycin (mTOR), as a family
member of PI3K-related protein kinases including ATM, ATR, and
DNA-PK, was also reported to be involved in DDR [18,19]. The
kinase activity of mTOR has been particularly known to integrate
nutrient/energy signaling with that of growth factor signaling [20–22]
in highly dividing tumor cells (TNBC cells characteristically exhibit a
high mitotic index), and RAD001 has been shown to sensitize tumor
cells to cisplatin-mediated DNA damage–induced apoptosis [19].
Recently, the dual PI3K-mTOR inhibitor NVP-BEZ235 has been
reported to inhibit ATM- and DNA-dependent protein kinase, cata-
lytic subunit (DNA-PKcs)–mediated DNA damage responses in
glioblastoma multiforme (GBM) cell lines [23].
PARPi are clinically effective in BRCA1/2-incompenent patients.
However, there exists a larger percentage of BRCA-competent TN
and/or basal-type BC patients who are outside the “BRCA box.” Here,
we identified, for the first time, the anti-DDR effect of GDC-0980 and
demonstrated that this effect brings an effective antitumor efficacy in a
BRCA-competent TNBC model when combined with ABT888 in the
presence of carboplatin. In a BRCA-competent model, GDC-0980
enhanced the antitumor activity of ABT888, in the presence of carbo-
platin, by inhibiting DDR in addition to its antiproliferative and pro-
apoptotic functions. Considering the importance of PARP as a target in
TNBC, and the existence of a large percentage of BRCA-competent
TN and/or basal-type BC patients, our data extend the realm of use
of PARPi in combination with dual PI3K-mTOR inhibitor plus carbo-
platin beyond the “BRCA box,” which merits further investigation to
test this combination in future phase I/II clinical trials.
The corollary that emerged from the concept of “synthetic lethality”
proposed by Tutt et al. [9], in the context of PARPi, was that a tumor
cell with high mitotic rates has an inherent limit to withstand the extent of
DNA-damage which is otherwise required to be corrected before the
cell enters mitosis. Because tumor cells of TNBC exhibit high mitotic
indices, the reliance of these cells on DDR should be high. In addition
to the error-free maintenance of tumor cell DNA, the high mitotic rate
in these TNBC cells with p53-null background demand 1) a higher rate
of cell cycle, 2) a reduced level of apoptosis, and 3) a challenging
nutritional/metabolic/protein translational state. In this study, we
attempted to exploit these characteristics of a BRCA-competent TNBC
tumor cell line to induce a higher magnitude of cell kill in vitro and
in vivo by choosing a combination of GDC-0980 with ABT888 plus
carboplatin. We hypothesized that a dual PI3K-mTOR kinase inhibitor,
in combination with PARPi plus carboplatin, would 1) sensitize a
tumor cell to PARPi (ABT888) through inhibiting/retarding the capac-
ity of the tumor cell to carry out PI3K-dependent DDR (endogenous as
well as inflicted by carboplatin) and 2) inhibit growth of the tumor by
counteracting the PI3K-mTOR–mediated survival/proliferative signals
from cell surface receptor(s) and nutrient milieu of the cell. Recently,
proteomic markers of DNA repair and PI3K pathway activation have
been shown to predict response to the PARPi BMN 673 in small cell
lung cancer [24]. In their study, Cardnell et al. demonstrated that
sensitivity to PARPi was associated with elevated baseline expression
levels of several DNA repair proteins, whereas greater drug resistance
was observed in small cell lung cancer models with baseline activation
of the PI3K-mTOR pathway. These observations complement our
work in which PI3K-mTOR inhibition has been shown to sensitize
BRCA1-competent TNBC model to PARP inhibition, suggesting
cooperation between DDR and PI3K pathway.
The armory of “targeted therapy” for the treatment of TNBC has
been inadequate because of the inherent complexity of TNBC biology,
the lack of “traditional” therapeutic targets, and the identification of
pathway-specific targets [25]. Recently, we have identified the role of
the Wnt–β-catenin pathway in the context of metastasis in TNBC and
revealed a mechanistic relationship between this pathway and the loss
of tumor suppressor PTEN [26,27]. Here, we report for the first time
that growth of a BRCA-competent TNBC tumor was blocked by a
combination treatment of a dual PI3K-mTOR inhibitor with a PARPi
in the presence of carboplatin. Our data identify the inhibition of DDR
as another mode of action of GDC-0980 and demonstrate that when
combined with carboplatin plus ABT888, GDC-0980 sensitized
BRCA-competent TNBC cells to PARPi to induce an effective anti-
tumor effect. This study demonstrates that an additional mechanism of
action of GDC-0980 is the inhibition of the PI3K pathway–dependent
DNA damage response, which is augmented by PARP inhibition owing
to an inability to respond to additional DNA damage induced by carbo-
platin. The latter provides additional support that PI3K and mTOR
regulate DNA damage responses both in vitro and in vivo and provides
a strong mechanistic rationale for the combination of the PI3K-mTOR
pathway inhibitors with PARPi in TNBC that are BRCA proficient
(a BC subtype in which PARPi are not active).
Materials and Methods
Cell Culture, Reagents, and Antibodies
TNBC cell lines (HCC70, HCC1143, HCC1937, MDA-MB231,
MDA468, and BT20) were obtained from American Type Cul-
ture Collection (ATCC, Manassas, VA) and cultured according to
standard protocols. Antibodies against pAKTS473, pAKTT308, AKT,
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pS6RPS235-236, S6RP, p4EBP1T37/46, 4EBP1, pERKT202/Y204, ERK,
cleaved PARP, a pro-apoptotic BH3-only of Bcl-2 family (BIM), and
cleaved caspases 3 and 9 (Cell Signaling Technology, Danvers, MA),
poly ADP-ribose (PAR) and PARP (Trevigen, Gaithersburg, MD), and
pγH2AXS139 (Novus Biologicals, Littleton, CO) were used for the
study. GDC-0980 and ABT888 were kindly supplied by Genentech,
Inc (South San Francisco, CA) and National Cancer Institute (NCI,
Bethesda, MD), respectively. In vivo studies were carried out using
ABT888 purchased from ChemieTek (Indianapolis, IN).
Biochemical Analysis
We tested the effects of ABT888 plus carboplatin and GDC-0980
(alone and in combination) on a panel of five to seven BRCA–wild-type
and BRCA-mutant TNBC cell lines. Normalized lysates (20-40 μg
protein) were resolved by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis for Western blot [28,29]. Doses of GDC-0980
(50 and 200 nM) and ABT888 plus carboplatin (2.5 and 10 μM)
were used for the in vitro study.
Cell Cycle Analyses and Apoptosis
Cells were trypsinized, fixed, and permeabilized in cold 70% etha-
nol and then washed with RPMI (phenol red free with 1% FBS)
and stained with 15 mg/ml propidium iodide (Sigma, St Louis, MO)
plus 10 mg/ml RNaseA (Sigma) before analysis by flow cytometry
(Accuri C6). To detect apoptosis, cells were resuspended in phosphate-
buffered saline (PBS) containing 4 mM CaCl2, 3% annexin V–
phycoerythrin (PE; BD Pharmingen, San Jose, CA), and 3% 7AAD.
Cells were analyzed by flow cytometry (Accuri C6).
Live/Dead Cell Assay and Immunofluorescence
We performed a fluorescence-based assay of live/dead cells using
fluorescence kit from Invitrogen (Molecular Probes, Grand Island,NY)
according to the manufacturer’s protocol. In short, treated cells grown in
24-well plates were washed with PBS and incubated with a 0.5 μMEth-
D-1 and 0.5 μM calcein AM solution in PBS for 30 minutes at room
temperature. Pictures were taken using an Olympus DP72 digital
camera. Confocal microscopy (Nikon A1 TIRFConfocal; Nikon Instru-
ments Inc, Melville, NY) was performed following immunofluorescence
(IF) staining [28] for cleaved caspase 3 (Alexa Fluor 488), Ki67 (Alexa
Fluor 647), and pγH2AXS139 (Alexa Fluor 488).
Clonogenic Growth Assay
Three-dimensional (3D) “ON-TOP” colony assay for anchorage-
dependent clonogenic growth was standardized with little modifica-
tionfrom Lee et al. [30]. Pictures of the live colonies were taken using
an Olympus DP72 digital camera. Soft agar assay for anchorage-
independent clonogenic growth was performed using cells embedded
in 0.4% low melt agar. Medium containing the drug treatment was
layered on top and changed every 5 to 7 days. Live colonies (14 days)
of cells were counted using an automated gel counter (Oxford Optronix;
Oxfordshire, United Kingdom).
Xenograft Study and Pharmacodynamic Marker Analysis
In vivo efficacy of the drug combination was evaluated in athymic
mice bearing established xenograft tumors following Institutional
Animal Care and Use Committee (IACUC) guidelines. Cells (5 × 106
MDA-MB231 cells; 2 × 106 MDA-MB468 cells) were suspended in
matrigel (50:50) and injected subcutaneously into the flank of immuno-
compromised female nude (nu/nu) mice, which were obtained from
Taconic Farms, Inc (Germantown, NY). Our pilot in vivo studies test
the effect of tumor on the overall health of the tumor-bearing mice to
comply with the National Institutes of Health (NIH) and our
institutional guidelines. The study showed that the tumors developed
from the MDA-MB468 cell lines have an inherent tendency to have
central necrotic areas especially when they tend to grow larger than
500 to 750 mm3 in volume. Our experience from previous studies
also show that it is because of the inherent nature of these PTEN-null
MDA-MB468 cell lines that tumors show central necrotic areas as the
volume of the tumor increases over time. In contrast, although tumors
from MDA-MB231 xenografts increase in volume more than tumors
from MDA-MB468 at the end of comparable time period, they do not
show any signs of central necrosis and mice remain in proper health and
ethical conditions for drug treatment. Considering the high burden of
necrotic tumors in animals of control groups in MDA-MB468 model,
we followed the advice of our institutional veterinarian to have 1) an
alternate day schedule of drug administration for GDC-0980 and 2)
halved the dose of ABT888 for the group of animals bearing MDA-
MB468 xenograft tumors (to maintain healthy body weights and
comply with ethical guidelines). Thus, to compare the effect the same
drug combinations between MDA-MB468 xenograft tumors and
MDA-MB231 xenograft tumors, we kept both the “starting tumor vol-
ume” and the “total days of drug treatment” constant, while we altered
the drug schedule in MDA-MB468 xenograft tumor–bearing animals.
After injection of tumor cells, tumors were monitored until they
reached mean tumor volumes of 150 to 300 mm3 and were distributed
randomly into groups of 8 to 10 animals per group [31]. GDC-0980
and GDC-0941 were formulated in 0.5% methyl cellulose/0.2%
Tween-80 and administered (10 mg/kg in 100 μl) through oral
gavage. ABT888 was administered orally. Carboplatin (Sanford Hos-
pital Pharmacy, Sioux Falls, SD) was reconstituted and diluted in saline
and dosed intravenously (i.v.) once on the first day of the treatment
cycle. Tumor volumes were determined by digital calipers using the
formula (L ×W ×W )/2 and expressed as mean relative tumor volume
(mm3). Tumor sizes and body weights were recorded twice weekly
over the course of the study. Mice with tumor volumes >2000 mm3
or with losses in body weight 20% or more from their weight at the start
of treatment were killed per institutional IACUC guidelines. For the
pharmacodynamic (PD) studies, tumors were analyzed for the markers
shown at the end of the treatment period. For marker analysis, immuno-
histochemistry (IHC) was performed on the paraffin-embedded tumor
tissue sections using Ki67, CD31, phosphorylated vascular endothelial
growth factor receptor (pVEGFR), cleaved caspase 3, phospho-S6RP,
and phospho-4EBP1 antibodies.
Statistical Analysis
All in vitro experiments were performed independently at least
three times in triplicates. Statistical analyses were carried out using
Microsoft Excel software. All numerical data are expressed as means ±
SD between triplicate experiments. Significant differences were analyzed
using Student’s t test and two-tailed distribution. Data were consid-
ered to be statistically significant if P < .001. Student’s t test is used
to evaluate differences observed between treated groups and vehicle-
treated controls. For in vivo studies, the overall P value for testing for
differences between two groups is <.05.
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Results
Dual Inhibition of PI3K and mTOR by GDC-0980 Alone
Changed the State of the Repair of DNA Damage in
BRCA-Competent TNBC Cells
Because PI3K signaling has been known to maintain HR steady
state [15] and inhibition of mTOR 1) suppresses HR and NHEJ
and 2) fails to recruit BRCA1 and RAD51 to DNA repair foci, an
essential step for HR [32], we investigated whether dual inhibition
of PI3K and mTOR would increase DNA damage in BRCA-
proficient TNBC cells including MDA-MB231, MDA-MB468,
HCC70, and BT20. We observed that GDC-0980 alone induced
PAR-rylation in TNBC cells. In PTEN-null MDA-MB468 cells,
200 nM of the drug increased PAR slightly as early as 3 hours after
treatment (Figure 1A, upper panel ), while PAR levels were signifi-
cantly high at both doses of GDC-0980 (50 and 200 nM) at 24
and 72 hours. In contrast, increases in PAR levels in RAS/RAF-
mutated MDA-MB231 cells were modest only around 72 hours
(Figure 1A, lower panel ). Interestingly, increase in PAR levels co-
incided with a concomitant increase of phosphorylated histone
2AX (pγH2AXS139), a DSB-related biomarker [33], levels in a dose-
dependent, time-dependent, and cell-specific manner (Figure 1B ).
Thus, dual inhibition of PI3K and mTOR resulted in an accumulation
of pγH2AXS139, a protein that is localized to the damaged DNA [34]
(to recruit effectors of DDR to these sites), which coincided with the
gain of accumulated product/marker of PARP enzyme activation, PAR
[35]. Levels of PAR, PARP, and pγH2AXS139 and the ratios of PAR/
PARP as well as PAR/pγH2AXS139 in MDA-MB468 (Figure 1, C and
D) and MDA-MB231 (Figures W1–W4) were semi-quantified from
the density of bands using ImageJ. IF localization of the focal
accumulation of pγH2AXS139 in MDA-MB468 cells after 24 hours
of GDC-0980 treatment showed a profound increase of pγH2AXS139
foci (marker for DSB; Figure 1E and Movies W1–W4). Ki67 IF de-
creased in MDA-MB468 cells after 24 hours of GDC-0980 treatment
(Figure 1F ). A similar increase in the levels of PAR and pγH2AXS139
were observed in HCC70 and BT20 cells following 24 and 72 hours of
the treatment of two doses of GDC-0980 (Figure 1, G and H ). Both
the levels of PAR and the ratio of PAR/PARP were significantly higher
than the untreated cells at both time points in HCC70 and BT20 cells
(Figure 1I ). A similar increase in the ratio of PAR/pγH2AXS139 was
also observed in both the cell lines following the GDC-0980 treat-
ment (Figure 1J ). Interestingly, the substantial increase in PAR levels
in PIK3CA-mutated BT20 cells at 72 hours was found to be dose
dependent (Figure 1G , right bottom panel ).
Dual Inhibition of PI3K and mTOR by GDC-0980 Enhanced
the State of DNA Damage in the Presence of Carboplatin plus
PARP Inhibitor ABT888 in BRCA-Competent TNBC Cells
Because of the inherent genomic instability in part owing to defi-
ciency in DDR [36], TNBC has been reported to be particularly sen-
sitive to chemotherapy. Because we observed that GDC-0980 alone
can induce a substantial impairment of DDR in BRCA-competent
cells, we hypothesized that addition of carboplatin would increase the
load of DNA damage at a given time and this load of DNA damage
would be enhanced in the presence of ABT888 that inhibits the capac-
ity of a tumor cell to repair SSBs. In this situation, addition of a dual
PI3K-mTOR inhibitor would be expected to induce apoptosis even
in BRCA-competent cells. To test this hypothesis, we treated the cells
with ABT888 plus carboplatin in combination with two doses of
GDC-0980. GDC-0980 alone and in combination with ABT888 plus
carboplatin enhanced DNA damage in TNBC cells (Figure 1), whereas
ABT888 alone or in combination with GDC-0980 plus carboplatin
decreased the ratio of PAR/PARP and PAR/pγH2AXS139 in TNBC
cells (Figures 1, W2 and W4).
We observed that while ABT888 plus carboplatin abrogated PAR
formation in both MDA-MB468 and MDA-MB231 cells, addition of
GDC-0980 caused a robust increase in pγH2AXS139 levels compared
to both controls, an effect more pronounced in MDA-MB468 cells
(Figure 1) at all time points tested. As expected, treatment with
ABT888 plus carboplatin blocked GDC-0980–induced PAR-rylation
in both cell lines at all time points (comparable to ABT888 plus carbo-
platin treatment only; Figure 1). Yang et al. [37] reported that ABT888
hits its therapeutic target by significantly reducing PAR levels and the
ratio of PAR to PARP-1 in human tumor cells as detected by IHC in
tumors from a phase 0 trial conducted at the NCI. Similar to their
study, we observed a reduction of PAR levels and the ratio of PAR
to PARP-1 in both MDA-MB231 and MDA-MB468 cells. Although
baseline PAR levels varied considerably between cell lines similar to
that was observed by Yang et al., in MDA-MB468 cells, PAR levels
Figure 1. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on DNA repair (PARP-mediated PAR formation),
DNA damage (pγH2AXS139), ratio of PAR/PARP, ratio of PAR/pγH2AXS139, and IF distribution of pγH2AXS139 in four BRCA-competent
TNBC cell lines. Expression of PAR (A) and pγH2AXS139 (B) by Western blot analysis of lysates from MDA-MB468 and MDA-MB231
treated with two doses of GDC-0980 (50 and 200 nM) alone or in combination with ABT888 (10 μM) plus carboplatin (10 μM) for different
time points. β-Actin was used as a loading control. The semi-quantification of expression levels (of the ImageJ intensities of protein
expression) of cellular PAR (upper panel), total PARP (middle panel), and ratio of PAR to total PARP (lower panel) (C), as well as
pγH2AXS139 levels (upper panel) and ratio of PAR to pγH2AXS139 (lower panel) (D) in MDA-MB468 cells before and after treatments
at different time points (3, 24, and 72 hours in successive darker shades) was shown as bar diagrams. Projection of 3D reconstituted
Z -sections of confocal images (Nikon A1 TIRF Confocal; Nikon Instruments Inc) shows pγH2AXS139 IF in MDA-MB468 cells treated with
200 nM GDC-0980 for 24 hours (E). A merged image of pγH2AXS139 IF shows nuclear pγH2AXS139 foci (fluorescein isothiocyanate;
green) with cytoplasmic filamentous actin (Phalloidin 555; red). Merged images of nuclear Ki67 (Alexa Fluor 647; visualized as pink
pseudocolor) IF in MDA-MB468 cells show a decrease in staining after 24 hours of GDC-0980 treatment (200 nM) (F). Expression of
PAR (G) and pγH2AXS139 (H) by Western blot analysis of lysates from HCC70 and BT20 treated with two doses of GDC-0980 (50 and
200 nM) alone or in combination with ABT888 (10 μM) plus carboplatin (10 μM) for different time points. β-Actin was used as a loading
control. The semi-quantification of expression levels (of the ImageJ intensities of protein expression) of cellular PAR (upper panel), total
PARP (middle panel), and ratio of PAR to total PARP (lower panel) (I), as well as pγH2AXS139 levels (upper panel) and ratio of PAR to
pγH2AXS139 (lower panel) (J) in HCC70 and BT20 cells before and after treatments at different time points (3 and 72 hours in successive
darker shades) was shown as bar diagrams.
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Figure 1. (continued).
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Figure 1. (continued).
Neoplasia Vol. 16, No. 1, 2014 PI3K-mTOR Pathway Controls DNA Damage Repair De et al. 49
Figure 1. (continued).
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Figure 1. (continued).
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and the ratio of PAR to PARP-1 were decreased from as early as 3 hours,
whereas in MDA-MB231 cells, the decrease was most pronounced at
72 hours following the treatment with ABT888 alone or in combi-
nation with GDC-0980 (Figures 1 and W2).
Inhibition of PARP has been shown to increase pγH2AX foci
formation, and this increase is thought to reflect the collapse of in-
creased number of unresolved spontaneously formed SSBs (following
PARP inhibition collapsing into DSBs at replication forks), which
then are the major lesions triggering spontaneous HR [38]. Dual
suppression of PI3K and mTOR by GDC-0980 enhanced the im-
pairment of DDR in the presence of carboplatin plus ABT888 more
than GDC-0980 alone or ABT888 plus carboplatin treatment. To
substantiate the feasibility of detection of PAR polymer in the cells,
we also determined pγH2AXS139 and expressed it as the ratio of
PAR/pγH2AXS139. Increased levels of pγH2AXS139 (more pro-
nounced in MDA-MB468) with an abrogation of PAR (as shown
by the decrease of PAR/pγH2AXS139 ratios) at all time points in
MDA-MB468 and at 72 hours in MDA-MB231 cells following
combination treatment demonstrated that inhibition of PARP had
a significant contribution to the induction of DSB (pγH2AXS139
levels; Figures W2–W4).
To test the effectiveness of the treatment of GDC-0980 either alone
or in combination with ABT888 plus carboplatin, we have included
two BRCA-competent cell lines in which PI3K pathway activation
has been reported to occur through two different ways, e.g., PTEN
nullness (HCC70) and activating mutation of PIK3CA (BT20) [17].
The data demonstrated that the pattern of changes in the levels of PAR
and pγH2AXS139 as well as the ratios of PAR/PARP and PAR/
pγH2AXS139 in HCC70 and BT20 TNBC cell lines following
the combination treatment at 24 and 72 hours was similar to that
observed in MDA-MB231 and MDA-MB468 cells (Figure 1, G–J ).
GDC-0980 Alone and in Combination with ABT888 plus
Carboplatin Inhibited Cellular Survival/Proliferative
Signals and Increased Cellular Apoptotic Signals in
BRCA-Competent TNBC Cells
The effect of GDC-0980 alone or in combination with ABT888 plus
carboplatin inhibited cellular survival/proliferative signals in MDA-
MB468 and MDA-MB231 cells (Figure 2). Treatment with GDC-
0980 caused a dose-dependent inhibition of pAKTT308, pAKTS473,
pP70S6K, and pS6RPS235-236 inMDA-MB468 cells at 3 and 24 hours.
Combination with ABT888 plus carboplatin inhibited pAKTT308more
than the pAKTS473, an effect similar to GDC-0980 treatment alone
along with the inhibition of pS6RPS235-236 at 3 hours (Figure 2, A
and B ). In MDA-MB231 cells, both GDC-0980 alone and in combi-
nation with ABT888 plus carboplatin decreased levels of pAKTT308,
pAKTS473, and pS6RPS235-236 at 3 hours, whereas the decrease in levels
of pAKTT308 and pS6RPS235-236 was restored at 72 hours. GDC-0980
alone and in combination with ABT888 plus carboplatin initially de-
creased both levels of p4EBP1T37/46 and pERKT202/Y204 dose depen-
dently at 3 hours; most of which were restored at 72 hours with the
exception of p4EBP1T37/46 for the combined treatment (Figure 2C ).
We observed that pERKT202/Y204 levels were restored at 72 hours after
initial decrease at 3 hours inMDA-MB231 cells (Figure 2). It is possible
that the restored levels of pERKT202/Y204 at 72 hours were responsible
for restored levels of pS6RPS235-236, p4EBP1T37/46, and pAKTT308.
Half maximal inhibitory concentration (IC50) of GDC-0980 is lower
for PI3Kα thanmTORkinase, whichmay explain in part the differences
in the downstream inhibition. A similar decrease in the levels of
pAKTS473, pAKTT308, pS6RPS235-236, and p4EBP1T37/46 was observed
inHCC70 and BT20 cells following the treatment of GDC-0980 alone
or in combination with ABT888 plus carboplatin (Figure 2,G andH).
Treatment with GDC-0980 in combination with ABT888 plus
carboplatin caused a significant increase of cleaved PARP in MDA-
MB468 cells starting as early as 3 hours until 72 hours (Figure 2D).
We also observed an increase in cleaved PARP following ABT888
plus carboplatin at 24 and 72 hours, which was absent in MDA-
MB231 cells. In MDA-MB468 cells, there was a differential
up-regulation of cleaved caspases 3 and 9 and BIM at 72 hours
(Figure 2E ). GDC-0980 in combination with ABT888 plus carbo-
platin induced cleaved PARP and increased the ratio of cleaved
PARP/t-PARP (Figure 2E , inset), a cleavage product of activated
(cleaved) caspase 3. As a consequence, we tested IF for cleaved
caspase 3 in the more sensitive MDA-MB468 cells at the highest time
point after drug treatment. Cytoplasmic IF for cleaved caspase 3 was
significantly increased in MDA-MB468 cells at 72 hours of treatment
with the combination of the drugs (Figure 2F ). A similar increase in the
levels of cleaved PARP as well as the ratio of cleaved PARP/total PARP
was observed in both HCC70 and BT20 cells following the treatment
of GDC-0980 alone or in combination with ABT888 plus carboplatin
Figure 2. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on cellular survival/proliferative signals, apoptotic
signals, and IF distribution of cleaved caspase 3 in four BRCA-competent TNBC cell lines. Expression of survival/proliferative (A–C) and
apoptosis markers (D–F) by Western blot and IF from cells treated with two doses of GDC-0980 (50 and 200 nM) alone or in combination
with ABT888 plus carboplatin for different time points using the indicated antibodies is presented. A comparison of the apoptosis markers
expressed at 72 hours of treatmentwith drugs betweenMDA-MB468andMDA-MB231 is shown inE. Inset showedchanges in expressionof
PARP, cleaved PARP (red rectangle; in the same blot), and the ratio of cleaved PARP/t-PARP in MDA-MB468. β-Actin was used as a loading
control. Cleaved caspase 3 expression in MDA-MB468 cells at 72 hours by IF (control and triple combination) is shown (F). Projection of
3D reconstituted Z -sections of confocal images (Nikon A1 TIRF Confocal; Nikon Instruments Inc) shows a merged image of cytoplasmic
cleaved caspase 3 IF (fluorescein isothiocyanate–conjugated cleaved caspase 3; green) with filamentous actin (Phalloidin 555; red) and
4′,6-diamidino-2-phenylindole (DAPI; blue) in XYZ axes (as shown in the pictures) in control (0.6-μm step size, 6.0-μm depth) and ABT888 +
carboplatin + GDC-0980–treated (0.6-μm step size, 5.4-μm depth) MDA-MB468 cells. Inset shows differential interference contrast
microscopy (DIC) image of the individual cells. Expression of survival/proliferative (G and H) and apoptosis markers (I and J) by Western blot
from HCC70 and BT20 cells treated with two doses of GDC-0980 (50 and 200 nM) alone or in combination with ABT888 plus carboplatin
for two different time points (3 and 72 hours) using the indicated antibodies is presented. I and J showed changes in expression of cleaved
PARP and cleaved caspase 3 (red rectangle; in the same blot) in HCC70 (I) and BT20 (J) cell lines. β-Actin was used as a loading control.
Insets of I and J showed changes in expression of the ratio of cleaved PARP/t-PARP in HCC70 (I) and BT20 (J) cell lines. β-Actin was used
as a loading control.
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Figure 2. (continued).
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(Figure 2, I and J ). However, the increases in the cleaved caspase 3
levels were more prominent at later time point (72 hours) in both
the cell lines (Figure 2, I and J , middle panel ).
GDC-0980 Alone and in Combination with ABT888 plus
Carboplatin Inhibited Cell Cycle Progression, Increased
Apoptosis, and Decreased Live/Dead Cell Ratios in
BRCA-Competent TNBC Cells
For the cell cycle progression study, TNBC cell lines in which the
PI3K/AKT pathway is activated in the absence of PTEN (MDA-
MB468) or an activating mutation of PI3K (BT20) and in which
the RAS/mitogen-activated protein kinases (MAPK) pathway is acti-
vated (MDA-MB231) were used. Flow cytometric analyses revealed
that although MDA-MB231 cells exhibited certain resistant charac-
teristics following treatment with ABT888 plus carboplatin, the G2
phase response of the cells to GDC-0980 was comparable to MDA-
MB468. Both cell lines showed an increase in annexin V positivity
following GDC-0980 alone or in combination with ABT888 plus
carboplatin at 48 hours. A dose-dependent increase in the G1 phase
population was observed following GDC-0980 in all cell lines tested
(Figures 3, A and B, and W5). This trend was preserved when com-
bined with ABT888 plus carboplatin. Treatment of cells with
ABT888 plus carboplatin decreased the G2 phase in MDA-MB468
cells compared to the other two cell lines. However, the decrease of
the G2 phase was observed following GDC-0980 in all three cell lines
irrespective of their mutation status. A dose-dependent increase in
the sub-G1 (G0) peak following GDC-0980 was also observed in
all cells by 24 hours of treatment, which persisted for 72 hours (data
not shown). Because we observed an increase in markers of apoptosis
(cleaved PARP, cleaved caspases 3 and 9, and BIM) following treat-
ment, we tested the early event of apoptosis at 48 hours. Annexin V/
7AAD staining indicated that GDC-0980 alone and in combination
with ABT888 plus carboplatin increased early events of apoptosis in
TNBC cells in a dose-dependent manner in both MDA-MB468 and
MDA-MB231 cells (Figure 3C ). In agreement with these data, the
combination of GDC-0980 with ABT888 plus carboplatin decreased
the live/dead cell ratios more profoundly in MDA-MB468 cells
(Figure 3D) compared to MDA-MB231 cells (data not shown).
We have also tested the effects of combination of GDC-0941 with
ABT888 plus carboplatin in vitro in the more sensitive and PTEN-
null MDA-MB468 cell line. GDC-0941 alone or in combination
with ABT888 plus carboplatin demonstrated 1) a trend in the in-
crease in the G1 phase and a decrease in the G2 phase of cell cycle
at 24 hours (Figure 3E ), 2) an increase in the annexin V positivity of
cells at 48 hours (Figure 3F ), and 3) a decrease in 2D colony forma-
tion on soft agar (Figure 3G ).
GDC-0980 Alone and in Combination with ABT888 plus
Carboplatin Attenuated an Anchorage-Dependent and
Anchorage-Independent Clonogenic 3D Growth in
BRCA-Competent TNBC Cells
Since we observed a decrease in proliferative signal and an increase
in proapoptotic signal as well as increase in apoptosis following drug
treatment, we tested the effect of the drug combination on clono-
genic growth of these cells. GDC-0980 dose dependently blocked
colony formation in 3D ON-TOP assay (Figure 4, A and B) as well
as in soft agar assay (Figure 4C ). Although a combination of GDC-
0980 with ABT888 plus carboplatin had a synergistic inhibitory effect
on colony formation by both soft agar assay and 3D ON-TOP assay in
MDA-MB468 and MDA-MB231 cells (Figure 4C), we observed that
consistent with our previous results, the highest dose of GDC-0980
(200 nM) completely blocked colony formation synergistically in
combination with ABT888 plus carboplatin in MDA-MB468 cells.
Interestingly, the lower dose (50 nM) of GDC-980 in the MDA-
MB468 soft agar assay also significantly blocked colony formation
synergistically in combination with ABT888 plus carboplatin. How-
ever, the highest dose of GDC-0980 (200 nM) in combination with
ABT888 plus carboplatin failed to bring a comparable level of inhibi-
tion of the formation of colonies in MDA-MB231 cells when com-
pared to GDC-0980 alone.
GDC-0980 Alone and in Combination with ABT888 plus
Carboplatin Is Efficacious in BRCA-Competent MDA-MB468
and MDA-MB231 Xenograft Models
The in vitro sensitivity profile of GDC-0980 alone and in combi-
nation with ABT888 plus carboplatin was recapitulated in vivo in
MDA-MB468 (Figure 5) and MDA-MB231 xenograft models (Fig-
ure 6), and the combination was efficacious in both the BRCA-
competent TNBC xenograft models tested. We also confirmed the
efficacy of combination in a more clinically relevant disease model
of TNBC, MDA-MB468 that does not expresses PTEN protein.
A combination of ABT888 plus carboplatin was typically efficacious
Figure 3. Effect of GDC-0980 and GDC-0941 alone and in combination with ABT888 plus carboplatin on cell cycle progression, apop-
tosis, and live/dead cells in BRCA-competent TNBC cell lines. Effect of two doses of GDC-0980 (50 and 200 nM) alone or in combi-
nation with ABT888 (2.5 μM) plus carboplatin (2.5 μM) on cell cycle distribution in MDA-MB468 (A) and MDA-MB231 (B). Cells were
treated as indicated for 24 hours. Cells were released and ethanol fixed before staining with propidium iodide for analysis by flow cytom-
etry. (C) Effect of GDC-0980 (50 and 200 nM) alone or in combination with ABT888 plus carboplatin on apoptotic (early) response
analyzed by annexin V/7AAD staining in MDA-MB468 and MDA-MB231. Cells were treated for 48 hours, released, rinsed, and placed
in annexin V binding buffer. Cells were labeled with annexin V–PE and 7AAD for analysis. Error bars represent SEM from triplicates.
(D) Effect of GDC-0980 in combination with ABT888 plus carboplatin on live (green)/dead (red) cells in MDA-MB468 cells was shown.
The merged image is shown to depict the live/dead cells. The dead cells were separately shown in the right panel. Effects of GDC-0941
(500 and 1000 nM) alone or in combination with ABT888 (2.5 μM) plus carboplatin (2.5 μM) on cell cycle distribution (E) and on apoptotic
(early) response analyzed by annexin V/7AAD staining (F) in MDA-MB468. Cells were treated as indicated for 24 hours for the cell cycle
analyses and 48 hours for annexin V/7AAD staining. Effect of GDC-0941 alone and in combination with ABT888 plus carboplatin on 2D
clonogenic growth under anchorage-independent conditions in MDA-MB468 TNBC cells is presented (G). MDA-MB468 cells were plated
under anchorage-independent conditions (soft agar assay) for 10 to 15 days and pictures of live colonies were taken (Olympus DP32;
original magnification, ×4). Cell colonies were counted using an automatic gel counter. Data represent bar diagrams of the number of
colonies (percentage of controls) in the respective groups of three independently performed experiments.
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in the MDA-MB468 xenograft model in which the PI3K-mTOR
pathway was activated because of genetic alterations associated to the
loss of PTEN protein. In this model, delay in tumor growth (stasis)
was achieved at the 10 mg/kg dose administrated every other day
compared to the daily dose of GDC-0980 in the MDA-MB231
model. In the MDA-MB468 model, a comparable inhibition of tumor
growth was achieved with 12.5 mg/kg ABT888 (twice a day, for 5 days)
compared to 25 mg/kg ABT888 in the MDA-MB231 model. In
contrast to the MDA-MB468 model, MDA-MB231, the TNBC
cell line/xenograft model that harbors mutations in KRAS or BRAF,
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was less sensitive to GDC-0980 alone (nonsignificant decrease of the
established tumor) and in combination with ABT888 plus carbo-
platin. However, a significant reduction of tumor growth was achieved
following the combination of ABT888 plus carboplatin and GDC-
0980 in this xenograft with a higher dose of ABT888 and a more
frequent dosing of GDC-0980 compared to the combination regi-
men used in the MDA-MB468 model. Single agent treatment of
GDC-0980 was well tolerated with less than 10% body weight loss
observed compared with vehicle controls in both models (Figures 5A
and 6A). In the MDA-MB468 model, while carboplatin alone or
GDC-0980 alone showed a trend (nonsignificant) of decrease in tumor
growth, ABT888 plus carboplatin combination was efficacious.
When tested in vivo, GDC-0980 in combination with ABT888 plus
carboplatin induced tumor stasis in the MDA-MB468 xenograft
Figure 3. (continued).
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model, at doses where each single agent was ineffective. The result of
our study showed that although comparable inhibitions of tumor
growths were observed in both models using the same drug combina-
tions, the efficacy of the combination was higher in MDA-MB468.
This is because of the fact that the drug schedule for GDC-0980 was
more frequent (daily injections) as well as the drug dose for ABT888
was double (25 mg/kg) in the MDA-MB231 model compared to
an alternate day of GDC-0980 injections and 12.5 mg/kg injection
of ABT888 in the MDA-MB468 model. On the contrary, we have
observed that pan-PI3K inhibitor GDC-0941 in combination with
ABT888 plus carboplatin failed to inhibit the growth of the established
tumors in the MDA-MB231 xenograft model when compared with
GDC-0980 (Figure 6F ).
To further investigate the mechanism of action of GDC-0980
alone or its combination with ABT888 plus carboplatin on tumor
growth inhibition, expression levels of proliferative marker (Ki67),
Figure 3. (continued).
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Figure 4. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on clonogenic growth under anchorage-dependent
and anchorage-independent conditions in BRCA-competent TNBC cells. MDA-MB468 (A) and MDA-MB231 cells (B) were plated under
anchorage-dependent conditions (3D ON-TOP assay) for 7 days and pictures of live colonies were taken (Olympus DP32; original mag-
nification, ×4). (C) Cells were plated in anchorage-independent conditions (soft agar assay) for 10 to 15 days with medium changes. Cell
colonies were counted using an automatic gel counter. Data represent bar diagrams of the number of colonies (percentage of controls)
in the respective groups of three independently performed experiments. D shows the schematic representation of the concept of com-
bination of dual PI3K-mTOR inhibitor with PARPi plus carboplatin in TNBC. Tumor cells of TNBC have high mitotic index. The high mitotic
index in these cells is maintained by 1) increased cell survival/proliferative signals, 2) decreased apoptosis signals, 3) decreased geno-
toxic exposure, 4) high-fidelity transmission of genetic information through error-free maintenance of replicating DNA, and 5) a condu-
cive nutritional state, metabolic state, and protein/fatty acid synthesis. We provide a model to counter this oncogenic event by a
combination of dual PI3K-mTOR inhibitor and PARPi plus carboplatin in TNBC cells. The model is derived from the concept that to
ensure the high-fidelity transmission of genetic information, tumor cells have evolved mechanisms to respond to DNA damage by acti-
vating a complex DNA damage response pathway that includes cell cycle arrest, the transcriptional and post-transcriptional activation of a
subset of genes including those associated with DNA repair. The simple corollary that emerged from the concept of “synthetic lethality”
as proposed by Tutt et al., in the context of PARPi, is that tumor cells with high mitotic rates have a natural limit to withstand the extent of
DNA damage and a limited capacity to respond to the DNA damage that needed to be corrected before cells enter into the mitosis. The
model is based on the fact that an inability to respond properly to or repair DNA damage leads to triggering of programmed cell death and
apoptosis. The model predicts that 1) the load of DNA damage will be increased by carboplatin treatment, 2) cells’ capacity to repair the
damaged DNA will be limited following PARP inhibition and PI3K inhibition, 3) dual PI3K-mTOR inhibitor will decrease survival and pro-
liferative signals in cells and reduce cells’ ability to respond to the posing nutritional/metabolic/protein synthesis load pertinent to the
mitosis, and 4) inhibition of mTOR, a homeostatic ATP sensor of the cell integrating nutrient/energy signaling with that of growth factor
signaling, will decrease proliferative signals in cells. The combination treatment with a dual PI3K-mTOR inhibitor and PARPi plus carbo-
platin in a tumor cell will incline the balance toward the proapoptosis state from the promitosis state.
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apoptosis marker (cleaved caspase 3), and angiogenic markers (CD31
and pVEGFR) were determined by IHC from the formalin fixed
paraffin embedded (FFPE) sections of the tumors obtained from
the animals (each arm of the xenograft study). High expression
of Ki67 has been associated with worse outcomes, and the mea-
surement of Ki67 index pre-therapy and post-therapy provided an
accurate surrogate for responsiveness of BC to the treatment [39].
PD studies showed a decrease in the Ki67, CD31, and pVEGFR
expression with a concomitant increase in cleaved caspase 3 staining
in tumors from mice treated with GDC-0980 in combination with
ABT888 plus carboplatin compared to the control (Figures 5, B–E ,
and 6, B–E ). The maximum antitumor effect of GDC-0980 was
achieved in theMDA-MB468 xenograftmodel, which recapitulatedwith
the tumor volumes (Figures 5A and 6A). Collectively, GDC-0980
Figure 4. (continued).
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in combination with ABT888 plus carboplatin showed an on-target
activity in BRCA-proficient TNBC tumor models and more so in
models wherein the PI3K-mTORpathway is activated because of the loss
of PTEN protein. These results, in agreement with the in vitro obser-
vation, showed that GDC-0980 in combination with ABT888 plus
carboplatin was an efficacious antitumor drug combination in BRCA-
competent TNBC model, especially with a PTEN-null background.
Antitumor Effect of the Combination of GDC-0980 with
ABT888 plus Carboplatin Was Associated with the PD
Knockdown of Phosphorylated S6RPS235/236 and
Phosphorylated 4EBP1T37/46
Because our in vitro data showed that the combination treatment
with ABT888, carboplatin, and GDC-0980 dose and time depen-
dently blocked several key oncogenic molecules of the PI3K-mTOR
Figure 5. Efficacy of GDC-0980 alone and in combination with ABT888 plus carboplatin in a human tumor MDA-MB468 xenograft model.
A pilot study was conducted to determine 1) the number of cells required to inject for the establishment of tumors and their mainte-
nance in animals throughout the period of drug administration and 2) the maximum tolerable dose of drugs in animals with tumor
burden. The number of cells injected was adjusted on the basis of the tolerable tumor burden in untreated animals (following IACUC
guidelines). On the basis of the results of the pilot study, cells (MDA-MB468) were injected in matrigel subcutaneously into the flank of
immunocompromised female nude (nu/nu) mice. Established xenograft tumors were treated with GDC-0980 (10 mg/kg, oral, every
other day) alone and in combination with ABT888 (12.5 mg/kg in 0.9% NaCl [PH4.0], oral gavage, twice a day, for 5 days) plus carboplatin
(100 mg/kg, i.v. once) (A). The table (lower panel of A) shows the change in volumes of MDA-MB468 xenograft tumors and body weights
of the mice in response to drug combinations. PD data for Ki67 (B), CD31 (C), pVEGFR (D), and cleaved caspase 3 (E) were presented.
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pathway that were responsible for signaling the proliferation of tumor
cells including phosphorylated S6RPS235/236 and phosphorylated
4EBP1T37/46, we also tested the levels of phosphorylated S6RPS235/236
and phosphorylated 4EBP1T37/46 in the FFPE sections from tumor
samples obtained from xenograft studies (Figures 5A and 6A). Our
PD data demonstrated that phosphorylated S6RPS235/236 and phos-
phorylated 4EBP1T37/46 were decreased following the treatment of
the tumor-bearing mice with ABT888, carboplatin, and GDC-0980
in both xenograft models (Figure 7,A–D). Results showed that although
no changes in the levels of phosphorylated S6RPS235/236 and phosphor-
ylated 4EBP1T37/46 were observed after the treatment with ABT888
alone, the treatment of both carboplatin alone and GDC-0980 alone
as well as their combinations clearly decreased the IHC levels of
phosphorylated S6RPS235/236 and phosphorylated 4EBP1T37/46. As
expected, the highest levels of inhibition were observed following the
triple combination of ABT888, carboplatin, and GDC-0980.
Figure 5. (continued).
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Discussion
DDR machinery is fundamental to processes of tumorigenesis [40].
PARPi sensitivity and synthetic lethality have been reported to be cir-
cumstantial to the loss of BRCA-ness [41].We tested our hypothesis that
a node-specific inhibition of the PI3K pathway by GDC-0980 in the
presence of carboplatin would result in 1) an enhanced impairment of
DSB repair and 2) a subsequent sensitization to PARPi. This effect
occurring simultaneously with the inhibition of classic PI3K-mTOR
survival signal(s) would induce a robust antiproliferative/proapoptotic
signal(s) in BRCA-competent TNBC cells. Thus, GDC-0980, in
Figure 6. Efficacy of GDC-0980 alone and in combination with ABT888 plus carboplatin in a human tumor MDA-MB231 xenograft model.
A pilot study was conducted to determine 1) the number of cells required to inject for the establishment of tumors and their maintenance
in animals throughout the period of drug administration and 2) the maximum tolerable dose of drugs in animals with tumor burden. The
number of cells injected was adjusted on the basis of the tolerable tumor burden in untreated animals (following IACUC guidelines). On the
basis of the results of the pilot study, cells (MDA-MB231) were injected in matrigel subcutaneously into the flank of immunocompromised
female nude (nu/nu) mice. Mice bearing breast cancer xenografts were treated with GDC-0980 (10 mg/kg, oral, daily) alone and in com-
bination with ABT888 (25 mg/kg in 0.9% NaCl [PH4.0], oral gavage, twice a day, for 5 days) plus carboplatin (100 mg/kg, i.v. once) (A).
The table (lower panel of A) shows the change in volumes of MDA-MB231 xenograft tumors and body weights of the mice in response
to drug combinations. PD data for Ki67 (B), CD31 (C), pVEGFR (D), and cleaved caspase 3 (E) were presented. A comparison between the
efficacies of GDC-0980 and GDC-0941 in combination with ABT888 plus carboplatin tested in a human tumorMDA-MB231 xenograft model
was presented (F). For the PD studies, tumors were analyzed for the markers shown at the end of the treatment period.
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combination with ABT888 plus carboplatin, profoundly attenuated the
growth of TNBC tumors in vivo. Here, we report for the first time that
a node-specific inhibition of the PI3K-mTOR pathway by GDC-0980
caused an impairment of DSB repair and resulted in a consequent sen-
sitization to ABT888 plus carboplatin treatment in a BRCA-competent
TNBC model (Figure 4D, schematics).
DNA damage (pγH2AXS139 foci, a marker of DSB) might cause
an increased PAR polymer formation through PARP activation.
Increased PAR levels along with increased ratios of PAR/PARP in
both MDA-MB468 (Figure 1) and MDA-MB231 (Figures W2–W4)
following the inhibition of PI3K and mTOR strongly indicated an
altered state of DNA damage/DNA repair. Because PI3K is reported
to control DSB repair and mTOR inhibition resulted in a significant
suppression of both HR and NHEJ, the increased PAR level (indicating
increased activation of PARP) and pγH2AXS139 levels following GDC-
0980 in our result could be explained by a disconcerted DDR in the
cell. The result that GDC-0980 alone induced PAR-rylation and
enhanced the ratio of PAR/PARP in TNBC cells, and GDC-0980–
induced PAR-rylation in BRCA-competent TNBC cells was blocked
by ABT888 (Figure 1) together indicated that the enhancement of
DNA-damaging effects in the presence of GDC-0980 were not directly
mediated through PARP inhibition. In this context it is worth mention-
ing that IC50 of GDC-0980 for DNA-PKcs (DDR enzyme responsible
for NHEJ) was previously reported in the nanomolar range similar to
that for PI3K and mTOR kinase [42].
A dose-dependent increase in pγH2AXS139 only at 3 and 24 hours
was observed in MDA-MB468, which was stabilized around 72 hours
of treatment of GDC-0980. Although we observed maximum PAR
formation and PAR/PARP ratio at 72 hours following GDC-0980 in
MDA-MB468 cells, pγH2AXS139 levels were restored to near control
at the same time (Figure 1). This indicated that the highest activation
of PARP as a result of presumably more DNA damage (over 72 hours)
did not lead to an increased/sustained DSB at 72 hours indicating, at
this longer time point, that a cellular equilibrium of DNA damage/
DDR was achieved in this cell. It is possible that the DSBs were re-
paired and restored by the BRCA-proficient RAD51 system of the
cell. Our argument is further supported by the fact that the same
doses of GDC-0980 when combined with ABT888 and carboplatin
induced a robust increase in pγH2AXS139 at 72 hours along with the
concomitant increase in 1) apoptosis markers (cleaved caspases 3 and
9, cleaved PARP, and BIM), 2) annexin V positivity, (3) percentage
of dead cells, and (4) IF of cleaved caspase 3.
We observed a characteristic difference between the responses of
MDA-MB231 and MDA-MB468 cells to the drugs in terms of PAR
and pγH2AXS139 levels and their ratios. PTEN-null MDA-MB468
cells were observed to be more sensitive and dose responsive not only
Figure 6. (continued).
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to the GDC-0980 treatment alone but also to the combination(s)
compared to RAS/RAF-mutated MDA-MB231 cells. There is an
accumulating body of evidence implicating the MAPK signaling
pathway in DNA repair and cell survival [43]. Weidhaas et al. [44]
have reported that the RAS/MAPK pathway signaling was genetically
linear with the DNA damage response pathway and acted down-
stream of the DNA damage checkpoint implicating involvement of
this pathway in DDR following cytotoxic drugs. Oncogenic HRAS
has been reported to enhance DNA repair [45]. DDR genes were
upregulated after epidermal growth factor receptor (EGFR)/RAS/
MAPK signaling [46,47]. There is measurable decrease in DNA
repair with EGFR pathway inhibition, and gefitinib treatment was
accompanied by inhibition of DDR and cell growth in oral cancer
[48]. In fact, tumors mediated by activating mutations or over-
expression of components of the EGFR signaling pathway were all
found to be resistant to cytotoxic therapy [49,50]. Our findings indi-
cate that enhanced repair of damage/resistance to response to DNA-
damaging drugs and PARPi in the tumor cell may be associated with
an upregulated RAS/MAPK pathway.
However, the absence of PTEN protein might also have contrib-
uted to the increased sensitivity and dose responsiveness in our study
not only to GDC-0980 treatment alone but also to the combinations
owing to PTEN’s transcriptional effect on the BRCA-RAD51 system
and its effect on genetic stability [51]. Shen et al. suggested a direct
impact of PTEN on transcriptional regulation of RAD51 [52], and
Baker reported increased nuclear foci of pγH2AXS139 following
Figure 6. (continued).
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PTEN RNAi [53]. A genetic inactivation of PTEN suppressed DNA
repair to induce a synergistic effect of olaparib in combination with
cisplatin [54]. Taken together, it is possible that the PTEN nullness
in our cells had a permissive role in mediating the effect of the com-
bination of GDC-0980 and ABT888 plus carboplatin. In the context
of TNBC, this has particular therapeutic/translational relevance due
to two reasons. First, the team of Kornelia Polyak [4] has recently
demonstrated the importance of PTEN loss in the relative temporal
order of somatic events associated with the basal-like subtype to show
that PTEN loss is the most common first event. Second, loss of
PTEN protein is observed in a significant percentage of the TNBC
patient population [6,51,55].
Inhibition of apoptosis through interaction with DDR enzyme–
associated signaling complex has been reported in human cancer cells
[56]. The differences in response to the drug combination in sur-
vival/proliferative signals between the two cell lines can be explain
by the RAS/RAF status of MDA-MB231 as previously reported by
Wallin et al. [57]. There is a regulatory mechanism for balancing
p53 and RAS/MAPK signaling [58]. Since inhibition of AKT leads
to transcriptional activation of receptor tyrosine kinases (RTKs)
through FOXO [59], we tested the phosphorylation status of EGFR/
total EGFR following GDC-0980. However, no change was observed
in pEGFR in our model system. The limited long-term (72 hours) ef-
fect of GDC-0980 on direct downstream of mTOR, p4EBP1T37/46,
and pP70S6K may be explained by a higher IC50 of GDC-0980 for
mTORC kinase than PI3K as reported earlier [42]. In a sharp contrast
to MDA-MB468 cells, there was an absence of induction of cleaved
PARP and also of other effectors of apoptosis including cleaved caspase
9 and BIM at any time following treatment in MDA-MB231 cells as
reported in an earlier observation [57]. Whether the observed dif-
ferences between cell lines were attributed to their basal-like (MDA-
MB468) or mesenchymal-like (MDA-MB231) behavior as recently
reported by Yi et al. [60] or were attributed to the KRAS/BRAF pathway–
mediated resistance for GDC-0980 [57] remains to be determined.
Consistent with our in vitro results, GDC-0980 in combination
with ABT888 plus carboplatin was found to be more efficacious in
the MDA-MB468 xenograft model when compared to MDA-
MB231. We observed a higher half maximal effective concentration
Figure 7. The PD knockdown of phosphorylated S6RPS235/236 and phosphorylated 4EBP1T37/46 in vivo following the treatment of GDC-
0980 alone and in combination with ABT888 plus carboplatin. Mice bearing breast cancer xenografts of TNBC cells (MDA-MB231 and
MDA-MB468) were treated with GDC-0980 (10 mg/kg, oral, daily) alone and in combination with ABT888 (25 mg/kg in 0.9% NaCl [PH4.0],
oral gavage, twice a day, for 5 days) plus carboplatin (100 mg/kg, i.v. once). PD data for phosphorylated S6RPS235/236 (A and C) and
phosphorylated 4EBP1T37/46 (B and D) for MDA-MB468 (A and B) and MDA-MB231(C and D) were presented. For the PD studies, tumors
were analyzed for the markers shown at the end of the treatment period.
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(EC50; 5 μM) value for GDC-0980 in this cell line in our study
(Figure W1) consistent with an earlier report [57]. The limited effect
to MDA-MB231 cells of the combination may be due in part by its
limited effect on cell cycle progression, ineffectiveness to induce
downstream apoptosis markers, lack of apoptosis, and high live/dead
cell ratios in vitro. In addition, the combination also had limited ef-
fect on PAR formation and levels of pγH2AXS139 in MDA-MB231.
One of the reasons that GDC-0980 alone had a limited effect on
MDA-MB231 was that it is a dual PI3K-mTOR inhibitor and cells
with RAS/RAF mutation background are specifically insensitive to
PI3K inhibitors. In line with this rationale, we observed that pan-
PI3K inhibitor GDC-0941 failed to show any efficacy in an
MDA-MB231 xenograft model (Figure 6F). This was consistent with
a previous report that in KRAS-mutant cells with an activated RAS/
MAPK pathway, survival is primarily mediated through the MAPK
pathway and potent inhibition of MAPK even with modest inhibition
of AKT could drive an increase in apoptosis [61]. Similarly, we also
failed to identify an up-regulation of any apoptotic marker(s) in our
in vitro experiments. Our PD data demonstrated that IHC expression
of cleaved caspase 3 in the tumors from the MDA-MB468 xenograft
model is higher compared to the matched controls in the tumors from
the MDA-MB231 model (Figures 5 and 6). Vijapurkar et al. demon-
strated that mTOR kinase inhibition had potent cytostatic effect but
did not induce apoptosis as a result of negative feedback inhibition
and/or maintenance of survival signaling. A significant cytotoxicity
was induced by a co-targeting mTOR kinase with the specific survival
pathways in diagnostically defined subpopulations, i.e., the PI3K
pathway in PI3K-mutant cells or the MAPK pathway in KRAS-
mutant cells [61]. Our PD data showed that highest levels of the
inhibition of phosphorylated S6RPS235/236 and phosphorylated
4EBP1T37/46 occurred in the tumors of the mice treated with the
triple combination of ABT888, carboplatin, and GDC-0980 (Fig-
ure 7). This result demonstrates the capacity of the combination of
ABT888, carboplatin, and GDC-0980 to affect a sustained knockdown
of phosphorylated S6RPS235/236 and phosphorylated 4EBP1T37/46
in vivo and indicates that the inhibition of the growth of the tumor
is mediated through the inhibition of oncogenic signals like phos-
phorylated S6RPS235/236 and phosphorylated 4EBP1T37/46.
In summary, we demonstrate that inhibition of DDR is another
mode of action of GDC-0980, and when combined with PARPi plus
carboplatin, GDC-0980 induces an effective antitumor effect in
BRCA-competent TNBC cells. Our combination exhibited the poten-
tial to kill BRCA-competent TNBC cells because carboplatin-induced
DNA damage was amplified by GDC-0980 and PARPi to make a large
flux of DSB that overwhelm the normal DDR capacity of these tumor
cells to induce apoptosis. Considering the importance of PARP as a
Figure 7. (continued).
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target in TNBC, and the existence of a large percentage of BRCA-
competent TN and/or basal-type BC patients, this combination has
a promise toward the treatment of BRCA-competent TNBC and thus
merits further investigation.
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Figure W1. EC50 of GDC-0980 in TNBC cell lines. Genetic backgrounds of the cells were tabulated.
Figure W2. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on ratios of PAR/PARP levels in MDA-MB231 at
different time points. The semi-quantification of expression levels (of ImageJ intensities of the protein expression) of cellular PAR (upper
panel), total PARP (middle panel), and ratio of PAR to total PARP (lower panel) in MDA-MB231 cells before and after treatments at
different time points (3, 24, and 72 hours in successive darker shades) was shown as bar diagrams.
Figure W3. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on pγH2AXS139 levels in MDA-MB231 at different
time points. The semi-quantification of expression levels (of ImageJ intensities of the protein expression) of cellular pγH2AXS139 levels
in MDA-MB231 cells before and after treatments at different time points (3 and 72 hours in successive darker shades) was shown as
bar diagrams.
Figure W4. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on ratios of PAR/pγH2AXS139 levels in MDA-
MB231 at different time points. The semi-quantification of expression levels (of the ImageJ intensities of protein expression) of ratios of
cellular PAR/pγH2AXS139 levels in MDA-MB231 cells before and after treatments at different time points (3 and 72 hours in successive
darker shades) was shown as bar diagrams.
Movie W1. Three-dimensional projection movie showing nuclear
pγH2AXS139 foci in vehicle-treated MDA-MB468 cells at 24 hours.
Movie W2. Three-dimensional projectionmovie showing the effect
of GDC-0980 alone on nuclear pγH2AXS139 foci in MDA-MB468
cells at 24 hours.
Movie W3. Three-dimensional projection movie showing the
absence of cytoplasmic cleaved caspase 3 in vehicle-treated MDA-
MB468 cells at 72 hours.
Movie W4. Three-dimensional projection movie showing abun-
dance of cytoplasmic cleaved caspase 3 in GDC-0980 + ABT888 +
carboplatin–treated MDA-MB468 cells at 72 hours.
Figure W5. Effect of GDC-0980 alone and in combination with ABT888 plus carboplatin on cell cycle progression in BT20. Effect of two
doses of GDC-0980 (50 and 200 nM) alone or in combination with ABT888 plus carboplatin (2.5 μM) on cell cycle progression after
24 hours in BT20 cells.
